MedTrace Logo

Effect of a GnRH Analog on Hepatic Steatosis

NCT06523530 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2026-02-03

No results posted yet for this study

Summary

Menopause increases the risk of metabolic dysfunction-associated steatotic liver disease (MASLD), possibly owing to the abrupt lack of estrogen. Gonadotropin-releasing hormone (GnRH) treatment in endometriosis is regarded as a model of pharmaceutical menopause. Thus, the effect of goserelin acetate, a GnRH analog that results in transient menopause, on hepatic steatosis and fibrosis will be evaluated in this study.

Conditions

  • Metabolic Dysfunction-Associated Steatotic Liver Disease
  • Nonalcoholic Fatty Liver
  • Endometriosis

Interventions

DRUG

Goserelin Acetate 3.6 mg inj, implant

3.6 mg (1ml) administered subcutaneously once every month for 6 months (totally 6 injections)

Sponsors & Collaborators

  • 424 General Military Hospital

    collaborator OTHER

  • Aristotle University Of Thessaloniki

    lead OTHER

Principal Investigators

  • Dimitrios A Anastasilakis, MD, PhDc · School of Medicine, Aristotle University of Thessaloniki

  • Athina I Gkiomisi, MD, PhD · 424 General Military Hospital, Thessaloniki, Greece

  • Dimitrios G Goulis, MD, PhD · School of Medicine, Aristotle University of Thessaloniki

  • Angelos Daniilidis, MD, PhD · School of Medicine, Aristotle University of Thessaloniki

  • Athanasios A Anastasilakis, MD, PhD · 424 General Military Hospital, Thessaloniki, Greece

  • Chrysi Nalmpantidou, MD · "G. Gennimatas" General Hospital, Thessaloniki, Greece

  • Stergios A Polyzos, MD, PhD · School of Medicine, Aristotle University of Thessaloniki

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-11-26
Primary Completion
2027-04-30
Completion
2027-10-31
FDA Drug
Yes

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06523530 on ClinicalTrials.gov